Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | RXRA | P19793 | 1/20 | 0.57 |
| ▸ | RXRB | P28702 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 2/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | PTPRC | P08575 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPRB | P23467 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | CDC25A | P30304 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23266730 | 0.95 | MAOB (0.70) | MAOBAPPNR4A2RXRARXRB | |
| SCHEMBL1702727 | 0.92 | APP (0.74) | MAOBAPPNR4A2RXRARXRB | |
| SCHEMBL22275947 | 0.86 | APP (0.82) | MAOBAPPNR4A2RXRARXRB | |
| SCHEMBL13439802 | 0.85 | APP (0.66) | MAOBAPPNR4A2RXRARXRB | |
| SCHEMBL8243338 | 0.85 | MAOB (0.66) | MAOBAPPNR4A2PPARDPPARA | |
| SCHEMBL13279971 | 0.83 | MAOB (0.73) | MAOBAPPPTPRCPTPN2PTPN1 | |
| SCHEMBL8241837 | 0.83 | MAOB (0.63) | MAOBAPPPPARDPPARAPTPRC | |
| SCHEMBL12732314 | 0.83 | APP (0.63) | MAOBAPPNR4A2RXRARXRB | |
| SCHEMBL18161366 | 0.82 | MAOB (0.71) | MAOBAPPPPARGPTPRCPTPN2 | |
| SCHEMBL18161374 | 0.82 | MAOB (0.66) | MAOBAPPPPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | claimed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | claimed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | MAOB 243/4885APP 3412/4885NR4A2 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.